Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.44 |
| ▸ | LATS1 | O95835 | 2/20 | 0.30 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.30 |
| ▸ | PRKCH | P24723 | 2/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.30 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.30 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.30 |
| ▸ | CCR4 | P51679 | 1/20 | 0.30 |
| ▸ | PRKCB | P05771 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19225723 | 0.87 | CYP2A6 (0.34) | CYP2A6LATS1LATS2ROCK2PRKCH | |
| SCHEMBL10285458 | 0.81 | CYP2A6 (0.47) | CYP2A6 | |
| SCHEMBL30459098 | 0.77 | CYP2A6 (0.47) | CYP2A6ROCK2 | |
| SCHEMBL30940058 | 0.77 | CYP2A6 (0.58) | CYP2A6ROCK2 | |
| SCHEMBL73676 | 0.75 | CYP2A6 (0.60) | CYP2A6 | |
| SCHEMBL25030031 | 0.74 | HTR6 (0.52) | CYP2A6 | |
| SCHEMBL10253539 | 0.74 | CYP2A6 (0.47) | CYP2A6LATS1LATS2ROCK2PRKCH | |
| SCHEMBL25029772 | 0.71 | CYP2A6 (0.39) | CYP2A6LATS1LATS2 | |
| SCHEMBL14438020 | 0.71 | CYP2A6 (0.51) | CYP2A6 | |
| SCHEMBL30489352 | 0.70 | AOC1 (0.39) | CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021444-B2 | Antiviral compounds | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-02-02 | — | — | US | disclosed |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-02-20 | — | — | US | disclosed |
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-10358453-B2 | Antiviral compounds | ALIOS BIOPHARMA, INC. (US) | 2019-07-23 | — | — | US | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9724351-B2 | Compounds for the treatment of paramoxyvirus viral infections | ALIOS BIOPHARMA, INC. (US) | 2017-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | CYP2A6 4346/4885LATS1 3614/4885LATS2 3624/4885 |
| US-11021444-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | CYP2A6 4346/4885LATS1 3614/4885LATS2 3624/4885 |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | CYP2A6 4346/4885LATS1 3614/4885LATS2 3624/4885 |
| US-10358453-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | CYP2A6 4346/4885LATS1 3614/4885LATS2 3624/4885 |
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | TGFBR1, TGFB2, TGFB1 | CYP2A6 594/4885LATS1 965/4885LATS2 1631/4885 |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TGFBR1, TGFB2, TGFB1 | CYP2A6 594/4885LATS1 965/4885LATS2 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.